These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 9150695)

  • 21. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas.
    Colao A; Merola B; Ferone D; Marzullo P; Cerbone G; Longobardi S; Di Somma C; Lombardi G
    Eur J Endocrinol; 1995 Aug; 133(2):189-94. PubMed ID: 7655643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.
    Duet M; Mundler O; Ajzenberg C; Berolatti B; Chedin P; Duranteau L; Warnet A
    Eur J Nucl Med; 1994 Jul; 21(7):647-50. PubMed ID: 7957351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnosis and treatment of pituitary adenomas.
    Chanson P; Salenave S
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
    Plöckinger U; Quabbe HJ
    Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR.
    Taboada GF; Luque RM; Neto LV; Machado Ede O; Sbaffi BC; Domingues RC; Marcondes JB; Chimelli LM; Fontes R; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2008 Mar; 158(3):295-303. PubMed ID: 18299461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.
    Lucas T; Astorga R; Catalá M;
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):471-81. PubMed ID: 12641631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
    Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
    Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
    Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
    Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa.
    Maiza JC; Vezzosi D; Matta M; Donadille F; Loubes-Lacroix F; Cournot M; Bennet A; Caron P
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):282-9. PubMed ID: 17524029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term octreotide therapy in growth hormone-secreting pituitary adenomas: evaluation with serial MR.
    Lundin P; Edén Engström B; Karlsson FA; Burman P
    AJNR Am J Neuroradiol; 1997 Apr; 18(4):765-72. PubMed ID: 9127047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery.
    Lucas-Morante T; García-Uría J; Estrada J; Saucedo G; Cabello A; Alcañiz J; Barceló B
    J Neurosurg; 1994 Jul; 81(1):10-4. PubMed ID: 8207509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
    Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
    Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.